[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"glycogenesis-2-acid-maltase-deficiency\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:glycogenesis-2-acid-maltase-deficiency":45},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":16,"targetDuration":19,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":26,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100100246",false,"NCT00567073","Pompe Pregnancy Sub-Registry","A Sub-registry to Observe the Effect of Alglucosidase Alfa or Avalglucosidase Alfa Treatment on Pregnancy and Infant Growth in Women With Pompe Disease","Inclusion Criteria:\n\nEligible women must:\n\n* be enrolled in the Pompe registry (NCT00231400)\n* be pregnant, or have been pregnant with appropriate medical documentation available.\n* provide a signed informed consent and authorization form(s) to participate in the Sub-Registry prior to any Sub-Registry-related data collection being performed.\n\nNote: It is recommended that pregnancy data be collected on eligible women regardless of infant enrollment. In the event of patients having multiple pregnancies, participation in this Sub-Registry is encouraged for each individual pregnancy.\n\nExclusion Criteria:\n\nThere are no exclusion criteria for this Sub-Registry","FEMALE",{"count":17,"type":18},20,"ESTIMATED","4 Years","OBSERVATIONAL","This Sub-registry is a multicenter, international, longitudinal, observational, and voluntary program designed to track pregnancy outcomes for any pregnant woman enrolled in the Pompe Registry, regardless of whether she is receiving disease-specific therapy (such as ERT with alglucosidase alfa or avalglucosidase alfa) and irrespective of the commercial product with which she may be treated. No experimental intervention is given; thus a patient will undergo clinical assessments and receive standard of care treatment as determined by the patient's physician.\n\nThe primary objective of this Sub-registry is to track pregnancy outcomes, including complications and infant growth, in all women with Pompe disease during pregnancy, regardless of whether they receive disease-specific therapy, such as ERT with alglucosidase alfa or avalglucosidase alfa.",[23,24,25],"Glycogen Storage Disease Type II (GSD-II)","Pompe Disease (Late-onset)","Glycogenesis 2 Acid Maltase Deficiency",[23,27,28,29,30,31],"GSD-II","Pompe Disease","Pompe Disease (Late-Onset)","Acid Maltase Deficiency Disease","Glycogenosis II","RECRUITING","2026-04-15",{"date":35,"type":36},"2026-04-16","ACTUAL",{"date":38,"type":36},"2007-06-18",{"date":40,"type":18},"2034-01-31",{"name":42,"class":43},"Genzyme, a Sanofi Company","INDUSTRY",35,""]